Time To Rake In Healthy Returns From Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology, Inc.(PBYI) shares saw a recent bid of $79.75 and 2.12M shares have exchanged hands in the recent trading session, yielding a 110.98% gain over the past week. The stock price increased 2.18% or $-1.7 versus $78.05 at the end of the prior session. This change led market cap to move at $2.89B, putting the price -0.31% below the 52-week high and 188.58% above the 52-week low. The company’s stock has a normal trading capacity of 1.63M shares while the relative volume is 1.30.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $89.43 while $105.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $15.57 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $60.00, which would be decrease of about -25% of its current value. The mean target of $90.00 should be compared with the price when the stock was languishing around $27.64 a share. And it remains to be seen which target price PBYI can achieve without sacrificing much as the company is holding a 122.58% gain for the past twelve months.

By historical standards, Puma Biotechnology, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts  above the average P/E ratio of 137.90 times earnings. For now, Puma Biotechnology, Inc. is the toast of Wall Street as its ABR stands at 1.70 with 3 out of 7 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Puma Biotechnology, Inc. has a 26.16% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Puma Biotechnology, Inc. has far performed well this year, with the share price up 159.77% since January. Over the past 2 quarters, the stock is up 72.25%, compared with a gain of nearly 113.52% for 3 months and about 99.62% for the past 30 days.

Last time, the company shocked Wall Street by reporting EPS of $-1.97, smashing the consensus of $-1.98 per share. Revenue for the quarter also killed consensus, coming in at $0M, compared to the consensus of 0M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-2.03. The company is expected to report EPS as high as $-1.86 and as low as $-2.23 per share. Similarly, full-year EPS forecasts have ranged between $-10.71 and $-7.18. The mean EPS estimate is $-8.47. On the other side, sales forecasts for the current quarter are $0M. The stock is expected to report revenue as high as $0M and as low as $0M per share. Similarly, full-year sales forecasts have ranged between $7.29M and $50M. The mean revenue estimate is $22.97M.

Over the last 5 years, Puma Biotechnology, Inc. has averaged a -44.40% YoY EPS growth rate. Analysts are expecting EPS growth rates to be at -11.30% this quarter and EPS estimate for next year reflect a 51.40% growth rate.




Sell-side analysts also have something to say about this company. RBC Capital Mkts analysts stated on 25/05/2017 that they maintained their Sector Perform rating. RBC Capital Mkts analysts stated on 02/03/2017 that they maintained their Sector Perform rating. Credit Suisse analysts stated on 22/09/2016 that they maintained their Outperform rating. Stifel raised its rating on Puma Biotechnology, Inc. to Buy on 21/09/2016 in a reversal from its prior Hold rating.

Leave a Reply

Your email address will not be published. Required fields are marked *